antibiotic-resistance
(2)
Tim Sweeney
Tim Sweeney is the co-founder and CEO of Inflammatix, a Sunnyvale molecular diagnostics company that reads the immune system instead of hunting for pathogens. A surgeon-turned-entrepreneur with an MD/PhD from Duke and a biomedical informatics background from Stanford, he built TriVerity, an FDA-cleared rapid blood test that measures 29 immune-response genes and uses machine learning to score the likelihood of bacterial infection, viral infection, and severe illness. He has raised more than $200 million to bring precision medicine to sepsis and critical care.
Michael Bigham
Michael F. Bigham is a veteran biopharmaceutical executive and investor who spent nearly a decade as Chairman and CEO of Paratek Pharmaceuticals, guiding the company through the FDA approval and commercial launch of NUZYRA (omadacycline) - a novel tetracycline-class antibiotic tackling drug-resistant bacterial infections. A Stanford MBA and CPA with roots in Gilead Sciences' early days, he has built, funded, and led companies across the full arc of drug development. He now operates as founder and managing director of Firebrand River Capital.